With
Colin Hyslop,
Jordana Sanft
The Federal Court dismissed Pharmascience Inc.'s (Pharmascience) motion to determine a question of law on the issue of whether a first person can commence an action under subsection 6(1)...
With
Kassandra Shortt
The Federal Court dismissed Apotex's application for judicial review of the Minister's decision to cancel the reconsideration process.
With
Christopher Guerreiro,
Chelsea Nimmo
The Federal Court has ordered that the trial of two actions brought under the post-CETA Patented Medicines (Notice of Compliance) Regulations (the Regulations), against two separate generics,
The US-Mexico-Canada Agreement (USMCA), which is set to replace NAFTA, concluded on September 30, 2018.
With
Christopher Guerreiro,
Kristin Wall
As we reported, Canada has joined a new trilateral trade deal called the United States-Mexico-Canada Agreement (USMCA).
With
Eric Bellemare,
Brian John Capogrosso,
Joanne Chriqui
As a result, Apotex could not have started to replace its real-world sales to its UK and Australia affiliates until a year after its real-world sales actually began.
With
Christopher Guerreiro,
Jordana Sanft,
Kristin Wall
As we reported, Canada implemented a single-track pharmaceutical patent litigation regime through amendments to the Patented Medicines (Notice of Compliance) Regulations (the Regulations) on September 21, 2017.
With
Eric Bellemare
Pour bien des téléspectateurs, le clou du spectacle lors du weekend du Super Bowl LII n'était pas le match de championnat ou le concert musical de la mi-temps mettant de Justin Timberlake.
With
Christopher Guerreiro
The Federal Court of Appeal has provided guidance on the meaning of "inventive concept."
With
Sofia Lopez Bancalari,
Louisa Pontrelli
The court granted Shire's motion to partially consolidate an application pursuant to section 6 of the Regulations and an impeachment action with respect to the same patent.
With
Kristin Wall
Major reforms to Canada's Patent Act are coming as the Canadian Parliament moves one step closer to ratifying the Comprehensive Economic and Trade Agreement (CETA).
With
Jonathan Chong,
Allyson Whyte Nowak
On March 13, 2017, Apotex filed for leave to appeal the Federal Court of Appeal's (FCA) decision addressing validity and infringement of AstraZeneca's Canadian Patent No. 1,292,693 (the 693 Patent) (reported here) with the Supreme Court of Canada (SCC).
With
Brian John Capogrosso,
Joanne Chriqui,
Chelsea Nimmo
The Court of Appeal held the trial judge did not err in her conclusion that it was not a proper case to apportion Apotex's profits.
With
Allyson Whyte Nowak,
David Yi
The Court of Appeal dismissed AstraZeneca's cross-appeal seeking punitive damages.
With
Chelsea Nimmo,
Kristin Wall
Janssen filed an application for leave to appeal with the Supreme Court of Canada (SCC) on December 9, 2016, with respect to the Federal Court of Appeal (FCA) decision addressing...
